Yahoo Finance

Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent approval. Ziihera is now available to prescribers in the U.S. at a wholesale acquisition cost price of about $35,500 for a 28-day cycle, the analyst noted. With the launch of Ziihera in biliary tract cancer and Phase 3 data in gastroesophageal adenocarcinoma due in Q2 of 2025, the firm believes the company is “well-positioned for shares to appreciate in 2025,” the analyst tells investors.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on JAZZ:

• ALX Oncology announces results from Phase 1b/2 trial

• Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines

• Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio

• Roche announces FDA approval of label expansion into biliary tract cancer

• FDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera